The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2018 | IMiDs induce hematopoietic malignancies
The mechanism for the previously unknown occurrence of thrombocytopenia and neutropenia in patients with myeloma treated with immunomodulatory drugs (IMiDs) has finally been understood from clinical trials by Suzanne Lentzsch, MD, PhD, of Columbia University, New York City, NY. Dr Lentzsch explains that IMiDs such as revlimid and pomalidomide act by downregulating critical transcription factors, including IKZF1, pushing stem cells into one lineage and stopping maturation of progenitor cells and platelets. This mechanism provides a basis for hematopoietic malignancies as indicated by low white blood cell counts and platelets in patients taking IMiDs. This interview was recorded from the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX.
